Role of Endothelium in Doxorubicin-Induced Cardiomyopathy

Albert Z. Luu, BSc; Biswajit Chowdhury, PhD; Mohammed Al-Omran, MD, MSc; Hwee Teoh, PhD; David A. Hess, PhD; Subodh Verma, MD, PhD

JACC: Basic to Translational Science (Dec 2018)

Role of Endothelium in Doxorubicin-Induced Cardiomyopathy

Albert Z. Luu, BSc,
Biswajit Chowdhury, PhD,
Mohammed Al-Omran, MD, MSc,
Hwee Teoh, PhD,
David A. Hess, PhD,
Subodh Verma, MD, PhD

Affiliations

Albert Z. Luu, BSc: Division of Cardiac Surgery, Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Toronto, Ontario, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada
Biswajit Chowdhury, PhD: Division of Cardiac Surgery, Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Toronto, Ontario, Canada
Mohammed Al-Omran, MD, MSc: Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada; Division of Vascular Surgery, Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Toronto, Ontario, Canada; Department of Surgery, University of Toronto, Toronto, Ontario, Canada; Department of Surgery, King Saud University, Riyadh, Kingdom of Saudi Arabia
Hwee Teoh, PhD: Division of Cardiac Surgery, Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Toronto, Ontario, Canada; Division of Endocrinology and Metabolism, Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Toronto, Ontario, Canada
David A. Hess, PhD: Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada; Division of Vascular Surgery, Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Toronto, Ontario, Canada; Molecular Medicine Research Laboratories, Krembil Centre for Stem Cell Biology, Robarts Research Institute, London, Ontario, Canada; Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada; Dr. David A. Hess, Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, Western University, 1151 Richmond Street, London, Ontario N6A 5B7, Canada.
Subodh Verma, MD, PhD: Division of Cardiac Surgery, Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Toronto, Ontario, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada; Department of Surgery, University of Toronto, Toronto, Ontario, Canada; Address for correspondence: Dr. Subodh Verma, Division of Cardiac Surgery, St. Michael’s Hospital, 8th Floor Bond Wing, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada.

Journal volume & issue: Vol. 3, no. 6
pp. 861 – 870

Abstract

Read online

Summary: The clinical use of doxorubicin in cancer is limited by cardiotoxic effects that can lead to heart failure. Whereas earlier work focused on the direct impact of doxorubicin on cardiomyocytes, recent studies have turned to the endothelium, because doxorubicin-damaged endothelial cells can trigger the development and progression of cardiomyopathy by decreasing the release and activity of key endothelial factors and inducing endothelial cell death. Thus, the endothelium represents a novel target for improving the detection, management, and prevention of doxorubicin-induced cardiomyopathy. Key Words: cardiomyopathy, doxorubicin, endothelium, heart failure

Published in JACC: Basic to Translational Science

ISSN: 2452-302X (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the circulatory (Cardiovascular) system
Website: https://www.journals.elsevier.com/jacc-basic-to-translational-science/

About the journal